Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 20 Source: CRO
- €240.3 million turnover
-
€211.7 million
profit - 162 employees
-
31st Dec 19 Source: CRO
- €212.4 million turnover
-
€188.9 million
profit - 165 employees
- 8 more years available »
Ranking
By Turnover
(€240.3 million)- 299th in Top Companies
- 40th in Health
- 35th in Pharma
- 48th in Manufacturing
By Employees
(162)- 646th in Top Companies
- 79th in Health
- 58th in Pharma
- 97th in Manufacturing
- 162
- €240.3 million
Employees
- Tim Shanahan General Manager
Latest News
- May 24 Harsh winter may compel Europe to ration gas, warns International Energy Agency
- May 24 Hungary and Poland hold up EU decisions on oil and corporate tax
- May 24 Over 700 objections lodged against €466m Dundrum apartment ‘concrete jungle’
- May 24 Stripe unveils new third party app marketplace
- May 24 Shares in UK energy companies slide over windfall tax fears